Dapagliflozin (Farxiga): How It Works, What It Treats, Doses, and Side Effects

What Is Dapagliflozin and What Does It Treat?

Dapagliflozin blocks the SGLT2 transporter in the kidney's proximal tubule, which normally reabsorbs about 90% of filtered glucose back into the bloodstream. By blocking this transporter, the drug forces roughly 60 to 80 grams of glucose per day into the urine, lowering blood sugar without requiring insulin secretion. The FDA first approved it under the brand name Farxiga in January 2014 for adults with type 2 diabetes, then expanded its label to heart failure with reduced ejection fraction (HFrEF) in May 2020, and to chronic kidney disease (CKD) with or without type 2 diabetes in April 2021.

The drug belongs to a class that now includes empagliflozin (Jardiance), canagliflozin (Invokana), and ertugliflozin (Steglatro). Dapagliflozin is distinct in holding all three of those approved indications simultaneously. Its mechanism requires at least partial kidney function to work, which is why the prescribing label sets eGFR thresholds. FDA prescribing information for Farxiga specifies that for the diabetes indication the drug should not be initiated when eGFR falls below 45 mL/min/1.73m2, and it should be discontinued if eGFR drops below 25 mL/min/1.73m2.

The American Diabetes Association's Standards of Care in Diabetes 2024 states: "In patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD, an SGLT2 inhibitor with demonstrated benefit is recommended as part of the glucose-lowering regimen independent of HbA1c." [1]

How Dapagliflozin Lowers Blood Sugar: The Mechanism in Detail

The SGLT2 protein sits on the luminal surface of the S1 segment of the proximal convoluted tubule. Under normal physiology the kidney filters roughly 180 grams of glucose daily and reabsorbs nearly all of it. Dapagliflozin binds competitively to SGLT2, reducing that reabsorption by approximately 40 to 50%. The remaining glucose spills into the urine (glucosuria), and plasma glucose falls.

Because the mechanism bypasses the pancreatic beta cell entirely, dapagliflozin does not cause hypoglycemia when used as monotherapy. That is a meaningful clinical advantage over sulfonylureas like glipizide, which stimulate insulin release regardless of prevailing glucose. Hypoglycemia rates with glipizide can reach 20% in clinical practice, compared to roughly 1% with dapagliflozin monotherapy. [2]

Glucosuria also carries a mild caloric deficit, around 240 kcal per day, which contributes to the modest but consistent weight loss seen across trials. The osmotic diuresis from glucosuria additionally lowers blood pressure by approximately 2 to 4 mmHg systolic in most studies, providing a secondary cardiovascular benefit independent of glucose control. [3]

Key Clinical Trial Evidence

DECLARE-TIMI 58 (Type 2 Diabetes Cardiovascular Outcomes)

The DECLARE-TIMI 58 trial randomized 17,160 adults with type 2 diabetes and either established atherosclerotic cardiovascular disease or multiple cardiovascular risk factors to dapagliflozin 10 mg or placebo. After a median follow-up of 4.2 years, dapagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 17% (absolute rate 4.9% vs. 5.8%, hazard ratio 0.83 to 95% CI 0.73 to 0.95, P<0.005). [4] The MACE-3 endpoint (cardiovascular death, myocardial infarction, or stroke) did not show superiority, but the heart failure benefit was consistent across subgroups.

DAPA-HF (Heart Failure with Reduced Ejection Fraction)

DAPA-HF enrolled 4,744 patients with HFrEF (ejection fraction <40%) regardless of whether they had type 2 diabetes. Dapagliflozin 10 mg reduced the primary composite of worsening heart failure or cardiovascular death by 26% (hazard ratio 0.74 to 95% CI 0.65 to 0.85, P<0.001) compared to placebo. [5] About 42% of participants did not have diabetes at baseline, and the benefit was similar in both diabetic and non-diabetic subgroups. That finding shifted prescribing practice: cardiologists began prescribing dapagliflozin for HFrEF patients with normal glucose.

DAPA-CKD (Chronic Kidney Disease)

DAPA-CKD randomized 4,304 patients with CKD (eGFR 25 to 75 mL/min/1.73m2 and urinary albumin-to-creatinine ratio 200 to 5 to 000 mg/g) to dapagliflozin 10 mg or placebo. The trial was stopped early for clear benefit. Dapagliflozin reduced the primary composite of sustained 50% eGFR decline, end-stage kidney disease, cardiovascular death, or kidney failure death by 39% (hazard ratio 0.61 to 95% CI 0.51 to 0.72, P<0.001). [6] Again, about 33% of participants did not have type 2 diabetes, confirming a kidney-protective effect independent of glucose lowering.

Dapagliflozin vs. Metformin: Which Comes First?

Metformin remains the first-line oral agent recommended by most guidelines for type 2 diabetes in patients without contraindications. It costs less than $10 per month as a generic, reduces HbA1c by 1.0 to 1.5%, and has decades of safety data. Dapagliflozin is currently recommended as second-line therapy in glucose-lowering algorithms, or as first-line therapy when a patient has co-existing heart failure or CKD regardless of HbA1c.

The 2024 ADA Standards list the following principle: "For patients with type 2 diabetes and heart failure, an SGLT2 inhibitor with proven heart failure benefit should be prescribed to reduce risk of heart failure hospitalization and cardiovascular mortality." [1] That recommendation applies even if HbA1c is already at target on metformin, which means these two drugs are frequently co-prescribed rather than used sequentially.

In head-to-head data from the CANTATA-M trial (N=796), dapagliflozin 10 mg produced comparable HbA1c reduction to metformin 2 to 000 mg at 24 weeks (roughly 1.1% vs. 1.2% reduction), but dapagliflozin produced statistically greater weight loss (2.1 kg vs. 0.7 kg, P<0.001) and greater systolic blood pressure reduction (4.0 mmHg vs. 0.7 mmHg). [3] Gastrointestinal side effects were more common with metformin; genital infections were more common with dapagliflozin.

A practical decision point: if a patient tolerates metformin and has no cardiovascular or renal comorbidity, start with metformin. Add dapagliflozin when HbA1c remains above goal at 3 months, or at the first visit if the patient has CKD, HFrEF, or established atherosclerotic cardiovascular disease.

Dapagliflozin vs. Empagliflozin (Jardiance): How to Choose

Both dapagliflozin and empagliflozin are SGLT2 inhibitors with cardiovascular and renal outcome trial data. The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced cardiovascular death by 38% relative to placebo in patients with established cardiovascular disease. [7] DECLARE-TIMI 58, by contrast, enrolled a broader population including those with risk factors only, and its cardiovascular death benefit was more modest. Direct comparison is not possible because the trials used different populations.

A few practical differences exist. Empagliflozin holds an FDA indication specifically for reducing cardiovascular death in adults with type 2 diabetes and established cardiovascular disease; dapagliflozin's cardiovascular label focuses on reducing CV death or hospitalization for heart failure. For CKD, both drugs now have approved indications following the EMPA-KIDNEY trial (N=6,609), which showed empagliflozin reduced kidney disease progression or cardiovascular death by 28%. [8] Dapagliflozin's DAPA-CKD showed a 39% reduction, though again the populations differed.

From a formulary standpoint, dapagliflozin's generic became available in the U.S. in 2023, which may make it less expensive than brand-name empagliflozin for some patients.

Dapagliflozin vs. Pioglitazone (Actos): Contrasting Mechanisms

Pioglitazone activates PPAR-gamma receptors, improving insulin sensitivity in muscle and fat tissue. It lowers HbA1c by roughly 0.5 to 1.4% but causes fluid retention, weight gain of 2 to 4 kg, and an increased risk of bone fractures in women. The PROactive trial (N=5,238) showed pioglitazone reduced the secondary composite of cardiovascular events, though the primary composite endpoint did not reach significance. [9]

Dapagliflozin produces weight loss while pioglitazone causes weight gain. Both are reasonable second-line options, but the metabolic profile of dapagliflozin is generally preferred in patients with obesity, hypertension, or existing fluid retention. Pioglitazone may have a role in patients with non-alcoholic fatty liver disease because PPAR-gamma activation can reduce hepatic steatosis; dapagliflozin has no established hepatic benefit in that context.

Patients with New York Heart Association Class III or IV heart failure should generally avoid pioglitazone due to fluid retention risk. Dapagliflozin, by contrast, carries an indication to reduce HFrEF hospitalization.

Dapagliflozin vs. Glipizide (Sulfonylurea): Durability and Hypoglycemia

Glipizide and other sulfonylureas stimulate insulin secretion from pancreatic beta cells. They are inexpensive and lower HbA1c by 1.0 to 2.0%, but they cause hypoglycemia in 15 to 20% of patients and produce weight gain of 1 to 2 kg. Long-term data suggest beta-cell function declines more rapidly with sulfonylurea use than with SGLT2 inhibitors, possibly because continuous insulin hypersecretion accelerates beta-cell exhaustion.

The DURATION-R study and similar head-to-head datasets show SGLT2 inhibitors produce more durable glycemic control than sulfonylureas at 2 to 3 years because they do not depend on residual beta-cell capacity. For a patient already at risk for hypoglycemia (elderly, thin, irregular meal schedule), dapagliflozin is the mechanistically safer choice. Glipizide remains a reasonable option only when cost is the overriding concern and hypoglycemia risk has been assessed as low.

Farxiga Dosing: Standard Regimen and Titration

The approved oral regimen for type 2 diabetes starts at 5 mg once daily in the morning, with or without food. If additional glycemic control is needed and the drug is tolerated, the dose may be increased to 10 mg once daily. For heart failure and CKD indications, the approved dose is 10 mg once daily regardless of baseline glucose. [10]

No dose adjustment is required for mild-to-moderate hepatic impairment. For severe hepatic impairment (Child-Pugh Class C), the drug's pharmacokinetics shift enough that the prescribing label recommends caution. Renal function determines whether the drug will work, not just safety. When eGFR drops below 25 mL/min/1.73m2, glucose excretion becomes insufficient for meaningful glycemic effect, though the drug may still provide cardiovascular and renal benefits at lower eGFR for its non-diabetes indications.

Older adults over age 75 may need more careful monitoring because the combination of osmotic diuresis and any concurrent diuretic therapy can cause volume depletion and orthostatic hypotension. Starting at 5 mg and reassessing fluid status at 2 to 4 weeks is a reasonable approach in that population.

Side Effects and Safety Profile

Genital mycotic infections. The most common adverse effect. Glucosuria creates a substrate-rich environment in the perigenital area. Rates in Phase 3 trials were approximately 6 to 8% in women and 3% in men, compared to 1 to 2% in placebo groups. Most infections responded to a single course of topical antifungal therapy. [10]

Urinary tract infections. Rates were modestly elevated vs. placebo in some trials (approximately 4% vs. 3.5%), but the DECLARE-TIMI 58 analysis did not show a statistically significant increase in serious urinary tract infections. [4]

Diabetic ketoacidosis (DKA). Rare but serious. The mechanism involves a relative reduction in insulin secretion and an increase in glucagon, shifting metabolism toward ketogenesis even when blood glucose is not markedly elevated. This euglycemic DKA can be missed because clinicians may not check ketones when glucose appears near normal. The FDA added a boxed warning in 2015. Risk is higher in patients who fast, have surgery, or reduce insulin doses abruptly. Patients should be instructed to hold dapagliflozin 3 to 4 days before elective surgery and to check urine or blood ketones if they feel unwell. [10]

Fournier's gangrene. Extremely rare necrotizing fasciitis of the perineum. The FDA issued a safety communication in 2018 after 12 cases were identified across the SGLT2 inhibitor class. Patients should report any genital pain, redness, or swelling promptly. [11]

Volume depletion. Osmotic diuresis from glucosuria can lower blood pressure, which may be beneficial in hypertensive patients but problematic in those already on loop diuretics or ACE inhibitors at maximum doses. Reassess hydration status and consider temporarily reducing diuretic doses when initiating dapagliflozin.

Bone fractures and amputations. These safety signals emerged in trials with canagliflozin (CANVAS trial). DECLARE-TIMI 58 did not show a significant increase in fractures or amputations with dapagliflozin. [4] The class-wide FDA labeling mentions these risks, but dapagliflozin's specific dataset is reassuring.

Who Is a Good Candidate for Dapagliflozin?

The ideal candidate profile for initiating dapagliflozin includes type 2 diabetes with HbA1c above goal on metformin alone, or any patient with co-existing HFrEF or CKD regardless of glycemic status. Patients who are overweight, hypertensive, or intolerant of metformin's gastrointestinal side effects also benefit from the drug's secondary effects on weight and blood pressure.

Patients who should not receive dapagliflozin include those on dialysis, those with known hypersensitivity to the drug, and patients with type 1 diabetes (off-label use carries very high DKA risk). Pregnancy is a contraindication because animal studies showed fetal kidney toxicity during organogenesis; the drug should be discontinued when pregnancy is confirmed.

Patients with recurrent genital yeast infections, a history of euglycemic DKA, or who routinely fast for extended periods (such as during religious observance) require careful counseling and a plan for sick-day management before starting the drug.

Monitoring Parameters After Starting Dapagliflozin

At baseline, obtain a complete metabolic panel including eGFR, serum creatinine, and urinary albumin-to-creatinine ratio. Recheck eGFR and serum potassium at 4 weeks, because the volume depletion from osmotic diuresis can transiently reduce eGFR by 5 to 10%, a predictable hemodynamic effect rather than true nephrotoxicity. This initial eGFR dip does not indicate harm and should not prompt discontinuation; the longer-term trajectory in DAPA-CKD showed slower eGFR decline on drug vs. placebo. [6]

Check HbA1c at 3 months if the primary goal is glycemic control. Blood pressure should be assessed at the 4-week follow-up visit as well, given the expected 2 to 4 mmHg systolic reduction, and any antihypertensive regimen may need adjustment.

Annual reassessment of eGFR determines whether the glycemic efficacy threshold has been reached. If eGFR falls below 25 mL/min/1.73m2 and the patient's indication is type 2 diabetes only, the drug should be discontinued. If the indication is HFrEF or CKD, the current label permits continuation down to eGFR <25 mL/min/1.73m2 based on DAPA-CKD data showing benefit even at lower eGFR levels.